-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$30.60143.63% Upside
Stoke Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Stoke Therapeutics, Inc.?
Stoke Therapeutics, Inc. has been rated by research analysts at Leerink Partners, H.C. Wainwright, Canaccord Genuity, Needham, Credit Suisse in the past 90 days.